Dalfampridine Combined With Physical Therapy for Mobility Impairment in People With Multiple Sclerosis
MGH Institute of Health Professions
Summary
The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine? * Is the combined treatment associated with better outcomes than the medication (dalfampridine) on its own? * How do the individual treatments (dalfampridine, physical therapy) alone compare to each other? Participants with MS-related mobility deficits will: * Receive 6 weeks of dalfampridine treatment to assess the effects of this treatment. * After stopping the medication for 2 weeks, the investigators will re-evaluate walking, then randomly assign individuals to a 6-week physical therapy program. * Half of the participants will receive physical therapy while resuming dalfampridine treatment. The other half of the participants will receive physical therapy without resuming the medication. Researchers will compare the combination treatment group (medication plus physical therapy) to the physical therapy only group to see if the combined treatment improves walking-related function. Approximately 3 months after finishing the physical therapy program, participants will undergo a final evaluation to see if the treatment effects have been maintained.
Description
Multiple sclerosis (MS) is a degenerative disease process that disrupts the transmission of nerve impulses, resulting in a range of neurological signs and symptoms. Walking-related impairment is one of the most common symptoms, reported to affect more than 90% of people with MS. The leading non-pharmacological intervention for walking-related deficits in people with MS is rehabilitation, such as physical therapy. Rehabilitation is believed to restore function through experience-dependent neuroplasticity. There is strong evidence that physical therapy can improve mobility-related function in pe…
Eligibility
- Age range
- 25–75 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Confirmed diagnosis of MS * Expanded Disability Status Scale (EDSS) 6.5 or less * Timed 25-Foot Walk 6-45 seconds (average of 2 trials) * Able to stand unsupported for at least 10 seconds * Montreal Cognitive Assessment 23 or higher * Relapse free for at least 3 months * Not currently taking dalfampridine or not previously taken and discontinued due to adverse reactions * Not currently receiving physical therapy Exclusion Criteria: * Co-existing neurological disorders or orthopedic conditions affecting mobility and physical activity * Unable to follow a 3-step verbal c…
Interventions
- DrugDalfampridine 10 MG [Ampyra]
Dalfampridine (10 mg) every 12 hours for 6 weeks.
- BehavioralPhysical therapy
Physical therapy (motor relearning for mobility and balance) one-on-one twice per week for 6 weeks.
- OtherDalfampridine plus physical therapy
Dalfampridine (10 mg) every 12 hours for 6 weeks while simultaneously receiving physical therapy (motor relearning for mobility and balance) one-on-one twice per week.
Location
- MGH Institute of Health ProfessionsBoston, Massachusetts